FAM90A1 Inhibitors
Chemical inhibitors of FAM90A1 function through various molecular mechanisms to modulate cellular processes where this protein may play a role. Palbociclib, an inhibitor of CDK4/6, acts by obstructing the cell cycle progression, which can lead to a decreased requirement for FAM90A1 activity, as its functionality is potentially tied to proliferative states. Similarly, Alisertib targets the cell cycle by inhibiting Aurora A kinase, a protein crucial for mitotic events, thereby disrupting stages where FAM90A1 might be functionally important. Omipalisib and Triciribine take a different approach; the former impairs PI3K/mTOR signaling, while the latter inhibits the Akt pathway, both of which are pivotal for cell growth and survival. In doing so, these inhibitors can decrease the cellular context for FAM90A1 activity by altering survival and proliferation signals.
On the other hand, Leflunomide impedes pyrimidine synthesis by inhibiting dihydroorotate dehydrogenase, which is necessary for DNA replication, thus potentially reducing the cellular need for FAM90A1 activity. Bortezomib disrupts proteostasis by inhibiting the 26S proteasome, leading to protein accumulation and possibly affecting the cellular environment where FAM90A1 operates. Cobimetinib and Dasatinib, targeting MEK1/2 and Src family kinases and BCR-ABL respectively, alter different aspects of cell signaling and architecture, which can influence the operational context of FAM90A1. Marimastat impacts cell interaction and signaling by inhibiting matrix metalloproteinases, which may indirectly affect FAM90A1 functionality. Axitinib's inhibition of VEGFR-related pathways alters the cell survival context, which can limit the relevance of FAM90A1. Lastly, Venetoclax, by inhibiting Bcl-2, promotes apoptosis, potentially diminishing the cellular context in which FAM90A1 is active, whereas Thalidomide, through modulation of the cellular environment, can influence the functional role of FAM90A1.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Palbociclib | 571190-30-2 | sc-507366 | 50 mg | $315.00 | ||
Palbociclib inhibits CDK4/6, which are essential for cell cycle progression. Inhibition of these kinases can lead to reduced proliferation and could decrease the functional activity of FAM90A1 by limiting the cellular context in which it operates. | ||||||
GSK2126458 | 1086062-66-9 | sc-364503 sc-364503A | 2 mg 10 mg | $260.00 $1029.00 | ||
Omipalisib targets PI3K/mTOR signaling, a pathway involved in cell growth and survival. Inhibition of this pathway can diminish the context for FAM90A1 functionality as it may be reliant on signals regulated by PI3K/mTOR for its activity. | ||||||
Leflunomide | 75706-12-6 | sc-202209 sc-202209A | 10 mg 50 mg | $20.00 $81.00 | 5 | |
Leflunomide inhibits dihydroorotate dehydrogenase, leading to decreased pyrimidine synthesis, which is necessary for DNA replication. This inhibition can reduce the need for FAM90A1 activity by slowing down cell proliferation and DNA replication processes. | ||||||
Triciribine | 35943-35-2 | sc-200661 sc-200661A | 1 mg 5 mg | $102.00 $138.00 | 14 | |
Triciribine specifically inhibits the Akt pathway, which is involved in cell survival and growth. Inhibiting Akt can decrease the downstream effects necessary for FAM90A1’s functional role in the cell. | ||||||
MLN8237 | 1028486-01-2 | sc-394162 | 5 mg | $220.00 | ||
Alisertib inhibits Aurora A kinase, which plays a critical role in cell cycle progression, particularly during mitosis. Inhibition of Aurora A kinase can disrupt mitotic events where FAM90A1 might be functionally relevant. | ||||||
Cobimetinib | 934660-93-2 | sc-507421 | 5 mg | $270.00 | ||
Cobimetinib inhibits MEK1/2 leading to a halt in the MAPK/ERK signaling pathway, which is implicated in cell cycle regulation and growth. This can indirectly inhibit FAM90A1 by limiting cellular processes where its activity is required. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $47.00 $145.00 | 51 | |
Dasatinib is an inhibitor of Src family kinases and BCR-ABL. By inhibiting these kinases, it can affect adhesion and cytoskeletal dynamics, potentially disrupting the cellular environment in which FAM90A1 exerts its function. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $132.00 $1064.00 | 115 | |
Bortezomib inhibits the 26S proteasome, leading to the accumulation of proteins destined for degradation. This can interfere with the proteostasis of the cell, potentially inhibiting cellular contexts where FAM90A1 is active. | ||||||
Marimastat | 154039-60-8 | sc-202223 sc-202223A sc-202223B sc-202223C sc-202223E | 5 mg 10 mg 25 mg 50 mg 400 mg | $165.00 $214.00 $396.00 $617.00 $4804.00 | 19 | |
Marimastat is a broad-spectrum matrix metalloproteinase inhibitor. By inhibiting MMPs, it can affect the extracellular matrix and cell signaling, which may indirectly inhibit functional roles of FAM90A1 related to cell interaction and signaling. | ||||||
ABT-199 | 1257044-40-8 | sc-472284 sc-472284A sc-472284B sc-472284C sc-472284D | 1 mg 5 mg 10 mg 100 mg 3 g | $116.00 $330.00 $510.00 $816.00 $1632.00 | 10 | |
ABT-199 selectively inhibits the Bcl-2 protein, which is key for cell survival. By promoting apoptosis through Bcl-2 inhibition, the cellular context for FAM90A1 activity can be diminished. | ||||||